4D Molecular Therapeutics posts Q3 2025 results

4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025.

Accepted by SEC EDGAR 11/10/2025 - 08:17 AM EST Learn about SEC filing dates

Rhea-AI Filing Summary

4D Molecular Therapeutics, Inc. filed a current report to note that it has released its financial results for the three months ended September 30, 2025. The company furnished a press release titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” as Exhibit 99.1. The filing indicates that the release also covers recent operational developments and outlines milestones the company expects in the future.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did 4D Molecular Therapeutics (FDMT) disclose in this filing?

4D Molecular Therapeutics, Inc. disclosed that it has announced its financial results for the three months ended September 30, 2025, and furnished the related press release as an exhibit.

Which period do the latest 4D Molecular Therapeutics (FDMT) results cover?

The results discussed in the furnished press release cover the three months ended September 30, 2025.

What is included in Exhibit 99.1 for 4D Molecular Therapeutics (FDMT)?

Exhibit 99.1 is a press release dated November 10, 2025, titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones.”

Who signed the current report for 4D Molecular Therapeutics (FDMT)?

The report was signed by Ashoo Gupta, who is the Principal Financial and Accounting Officer of 4D Molecular Therapeutics, Inc.

On which exchange is 4D Molecular Therapeutics (FDMT) common stock listed?

4D Molecular Therapeutics, Inc. common stock, par value $0.0001 per share, is listed on the Nasdaq Global Select Market under the trading symbol FDMT.

Does this 4D Molecular Therapeutics (FDMT) filing discuss upcoming milestones?

The filing states that the furnished press release includes expected upcoming milestones, as reflected in its title, but the specific milestones are contained within the press release itself.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

0001650648false00016506482025-11-102025-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2025

4D Molecular Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-39782	47-3506994
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
5858 Horton Street #455
Emeryville, California				94608
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (510) 505-2680

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		FDMT		Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On November 10, 2025, 4D Molecular Therapeutics, Inc. (“4DMT”) announced its financial results for the three months ended September 30, 2025. A copy of 4DMT’s press release, titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones” is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit Number	Description
99.1	Press Release, dated November 10, 2025, titled “4DMT Reports Third Quarter 2025 Financial Results, Operational Highlights and Expected Upcoming Milestones”
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

			4D MOLECULAR THERAPEUTICS, INC.
Date:	November 10, 2025	By:	/s/ Ashoo Gupta
			Ashoo Gupta Principal Financial and Accounting Officer